This purchase order is for the testing 15 novel small molecule compounds using the kinase hotspot assay platform.
Ended Purchase Order Awarded Last action
- Contract number
- 75N95020P00081
- Awardee
-
Reaction Biology Corporation UEI LDBCLKM4WJH1
- Awarding agency
-
National Institute on Drug Abuse
National Institutes of Health, Department of Health and Human Services
- Obligated
- $118,430
Award facts
- Opportunity
-
- Kinase Assays: Testing 15 Novel Small Molecule Compounds using the Kinase HotSpot Assay Platform Solicitation · 75N95020Q00023 · Posted Jan 10, 2020
- Contract value 100% obligated
- $118,430.00 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- Funding agency
- National Center for Advancing Translational Sciences National Institutes of Health, Department of Health and Human Services
- NAICS code
- 541380 Testing Laboratories and Services
- PSC
- Q301 Reference Laboratory Testing
- Set-aside
- No set-aside
- Competition
- Not Competed under SAP · 1 offer Simplified Acquisition
- Pricing
- Firm Fixed Price
- Place of performance
- Malvern, PA 19355, USA
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Funding Only Action | -$720 | |
| Supplemental Agreement for work within scope | -$40 | |
| Original award | $119,190 |
About this award
This is a $118,430.00 firm fixed-price purchase order awarded by the Department of Health and Human Services' National Institutes of Health National Center for Advancing Translational Sciences to Reaction Biology Corporation, a self-certified small disadvantaged business. The contract is for testing 15 novel small molecule compounds using Reaction Biology's proprietary Kinase HotSpot assay platform. This work supports translational research efforts across the NIH. The purchase order was awarded on a sole source basis, as Reaction Biology was determined to be the only source capable of providing the required Kinase HotSpot assay services. There was no set-aside used for this award, which has a period of performance through January 30, 2021 and was issued under simplified acquisition procedures.
Quick answers
Who was awarded contract 75N95020P00081?
75N95020P00081 was awarded to Reaction Biology Corporation by National Institute on Drug Abuse (National Institutes of Health) on January 31, 2020.
How much is contract 75N95020P00081 worth?
The government has obligated $118,430 on 75N95020P00081.
Which agency awarded contract 75N95020P00081?
National Institute on Drug Abuse (National Institutes of Health) awarded 75N95020P00081, with funding from National Center for Advancing Translational Sciences (National Institutes of Health).
Was contract 75N95020P00081 competed?
The extent of competition for 75N95020P00081 was not competed under sap. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award